USA Trends and Developments Contributed by: David McIntosh, Matt Byron, Ryan Kramer, Sabrina Kim and Zoe Dettelbach, Ropes & Gray LLP
Conclusion The life sciences industry navigated a complex landscape in 2024, marked by a resurgence in public markets, robust venture investment, and a mixed M&A environment. Licensing deals – par- ticularly those involving biologics, later-stage assets, GLP-1-targeted therapies and GIP-tar- geted therapies – played a pivotal role in main- taining industry momentum. That complexity seems likely to multiply in 2025, as commenta- tors note that several key factors are poised to shape the sector’s trajectory. The impending patent cliff for a number of block- buster drugs is expected to drive increased licensing and M&A activity as companies seek to fill gaps in their pipelines. Advances in AI and the growing consumerisation of obesity-related drugs will likely continue to influence innovation and market dynamics. The increasing impor- tance of Chinese-manufactured molecules and collaborations between US and Chinese biotech firms may also play a significant role in shaping the industry’s future. Finally, the new adminis- tration’s policies on antitrust, healthcare, and international relations will introduce opportuni- ties and uncertainties alike.
While there are concerns in the industry regard- ing the volatile personalities in the Trump admin- istration, economists predict that a bump for the market could come in the form of signifi- cant tax reductions enacted by the Republican majority in Congress. Tax cuts such as the ones President Trump has supported would give big pharma companies massive tax breaks, accord- ing to Public Citizen. That said, the boost to the industry that these tax breaks could provide may be tempered by proposed tariffs on countries including Canada, Mexico and China. BioPhar- maDive, reports that Trump’s “America First” approach to international relations could give the Biosecure Act – a national security bill that would have the effect of limiting US companies’ freedom to contract with certain named Chinese service providers – a better chance of passage, which could create hardships for US companies that are dependent on these Chinese compa- nies. Given all of these various and conflicting fac- tors, the only certainty may be uncertainty. As Priya Chandran (leader of the Boston Consulting Group’s biopharmaceuticals team) expressed to Endpoints News at the JP Morgan Healthcare Conference in January, nobody “is in any posi- tion to predict exactly” what the ultimate impact on the life sciences sector will be.
396 CHAMBERS.COM
Powered by FlippingBook